These findings suggest that CD47 could be a useful molecular target for therapeutic intervention to control fungal infections, but the humanized CD47 antibodies that have recently entered clinical trials may adversely affect the control of candidiasis in cancer patients. The gene discussed is CD47; the disease is candidiasis.